Loading stock data…
$458.27+6.15 (+1.36%)
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Madrigal Pharmaceuticals, Inc. in the Healthcare sector is trading at $458.27 with a market capitalization of $11.7B. Wall Street consensus targets $682.11 (18 analysts), implying a +48.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $615.00, remaining 9.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $364.25M↑ | $311.34M↓ | $321.08M↑ | $287.27M↑ | $212.80M |
| Gross Profit | $324.25M↑ | $284.49M↓ | $296.63M↑ | $269.15M↑ | $203.74M |
| Operating Income | -$56.31M↑ | -$92.72M↓ | -$59.61M↑ | -$113.97M↓ | -$47.20M |
| Net Income | -$57.94M↑ | -$94.39M↓ | -$58.58M↑ | -$114.19M↓ | -$42.28M |
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...